Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

Overview of attention for article published in New England Journal of Medicine, March 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 15 news outlets
blogs: 12 blogs
policy: 3 policy sources
twitter: 52 X users
patent: 32 patents
facebook: 11 Facebook pages

wikipedia: 4 Wikipedia pages
googleplus: 1 Google+ user
reddit: 3 Redditors
f1000: 1 research highlight platform
guideline: 17 clinical guideline sources

Readers on

mendeley: 880 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 12 public wall posts from 11 users.

BreakFree Medicine by Dr Sarah LoBisco, 20 Aug 2015

The cholesterol dance continues! New cholesterol drug approved: https://www.youtube.com/watch?v=-qFTICwvDPY Concern for safety…

Société des sciences vasculaires du Québec, 27 Jul 2015

L'alirocumab...La FDA vient tout juste de l'approuver! Plusieurs études ont été réalisées avec cette nouvelle molécule et…

MedArt, 05 Jun 2015

#medArt freut auf Dr. Th. Burkard zum Thema "Kardiovaskuläre Prävention". Lesen Sie dazu auch folgenden Artikel: http://ow.ly/NS0…

Internet Medical Association, 29 Apr 2015

Related Articles Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16;372(16…

This page shows the most recent Facebook posts that mention this research output. Click here to find out how to access more activity, including 8 additional Facebook posts.